Legacy App users can now access the Health Portal – just reset your password using email as username.

HCG – Bodybuilders to TRT – Side Effects, Properties, and Uses

HCG – Bodybuilders to TRT – Side Effects, Properties, and Uses

Member Access Required

Sign in or join the Health Portal to watch this video.

Join Now

Timeline

Timestamp
Topic
00:00
He introduces hCG as a long‑standing hormone used by bodybuilders and some men on TRT. Modern use is framed around fertility support and recovery after steroid‑related shutdown.
01:01
He outlines early discovery and medical adoption, describing how production methods evolved over decades. The narrative contrasts historical enthusiasm with tighter modern prescribing standards today.
03:03
He describes the discontinued weight‑loss diet history and explains why evidence was not convincing. He adds that regulation differs by jurisdiction, even if federal control is limited.
04:47
He explains hCG structure and why its beta subunit gives it unique activity compared with similar hormones. The focus stays on testicular stimulation without claiming direct thyroid activation.
06:47
He compares intramuscular and subcutaneous kinetics and says route choice depends on dose and practicality. He emphasizes that firm comparative data are lacking, so personalization matters clinically.
08:20
He explains steroid‑related axis suppression and why LH and FSH signals drop during anabolic use. hCG is presented as a downstream stimulus that targets testicular cells directly.
10:05
He discusses classic post‑cycle regimens that pair hCG with other agents used in recovery planning. He notes that protocols are individualized, and he is pursuing more research clarity.
12:28
He raises concerns about Leydig and Sertoli cell desensitization when hCG is used too long. He also describes edema and higher estradiol as common unwanted outcomes in practice.
13:54
He reviews suggested dosing ranges for fertility maintenance and for men stopping testosterone to conceive. He emphasizes that many men recover fertility within months using structured dosing.
15:14
He explains that combining hCG with TRT can help reduce testicular atrophy for some men. He cautions that injection burden, cost, and uncertain long‑term data limit routine lifelong use.
16:15
He summarizes his preferred approach of simpler courses, conservative dosing, and clear goals. The final emphasis is using hCG as a tool, not a permanent shortcut for everyone.
16:44
He thanks viewers and closes by encouraging ongoing discussion about safer, evidence‑guided use. The conclusion frames hCG as helpful when appropriately supervised and time limited.

Video Summary

Human chorionic gonadotropin, often shortened to hCG, is presented as a long‑standing hormone therapy with evolving uses. It is described as historically used by bodybuilders on cycle and during post‑cycle recovery after stopping anabolic steroids. The discussion also notes use in men with low testosterone and in cases of anabolic steroid–induced hypogonadism. A short history follows, describing discovery in the 1920s and medical introduction in the early 1930s. Early manufacturing methods are described, including pituitary extracts and later purification from the urine of pregnant women. The presenter highlights that older medical literature listed many indications that are no longer accepted today. He stresses that modern prescribing has become more restricted and focused on fertility‑related indications.

The talk then shifts to pharmacology, describing hCG as a placental glycoprotein hormone with alpha and beta subunits. It is explained that the alpha portion resembles other pituitary hormones, while the beta portion drives hCG’s unique activity. The effect is framed as mimicking luteinizing hormone, stimulating Leydig cells and supporting testicular testosterone production. Differences in injection routes are discussed, with intramuscular dosing described as shorter acting than subcutaneous dosing. Because conclusive comparative studies are limited, dosing route is described as individualized and dependent on dose size. In performance‑drug contexts, hCG is described as a way to bypass suppressed pituitary signaling during steroid exposure. The presenter emphasizes that this does not restart the brain’s axis directly, but instead stimulates the testes downstream.

When hCG is combined with testosterone therapy, the presenter describes a debate about long‑term cell desensitization. He notes that some men report that testicular size support diminishes over time, even when doses are increased. Potential side effects are described, including systemic water retention and increased aromatization leading to higher estradiol. He also mentions observing possible cortisol or adrenal‑related changes in some laboratory patterns, while noting uncertainty. For men coming off steroids or aiming for fertility, he references newer physician literature discussing higher short‑term doses. He shares a practical preference for simpler, shorter courses and avoiding unnecessarily high dosing whenever possible. The closing message is that hCG can be valuable for fertility and recovery, but requires careful individual medical oversight.

Drug Callouts

Drug
Description
Human chorionic gonadotropin (hCG)
Human chorionic gonadotropin is an injectable hormone that mimics luteinizing hormone to stimulate testicular testosterone production. In the transcript it is discussed for fertility, post‑cycle recovery, and selective use alongside TRT.
Testosterone
Testosterone is the primary androgen hormone, and replacement therapy provides exogenous testosterone when endogenous levels are low. The transcript describes placing testosterone “to the side” during fertility attempts and contrasting it with hCG stimulation.
Clomiphene citrate
Clomiphene citrate is a selective estrogen receptor modulator that can increase gonadotropin signaling by reducing estrogen feedback at the hypothalamus. The transcript cites clomiphene as part of classic post‑cycle therapy, sometimes paired with hCG.
Tamoxifen
Tamoxifen is a selective estrogen receptor modulator used clinically for estrogen‑receptor positive conditions and for managing estrogen effects. The transcript mentions tamoxifen within older post‑cycle regimens, alongside other recovery agents.
Aromatase inhibitors
Aromatase inhibitors are medications that lower estrogen by blocking aromatase conversion of androgens into estradiol. The transcript notes they may be included in individualized recovery plans when estradiol rises during hCG use.

Condition Callouts

Condition
Description
Hypogonadotropic hypogonadism
Hypogonadotropic hypogonadism is a condition where pituitary gonadotropins are low, leading to reduced testicular testosterone production. The transcript lists this as a modern approved male indication for hCG therapy.
Anabolic steroid‑induced hypogonadism
Anabolic steroid‑induced hypogonadism is suppressed gonadal function that follows exogenous steroid use and axis shutdown. The transcript highlights emerging data and clinical use of hCG to help recovery in these men.
Infertility
Infertility is the inability to achieve pregnancy after sustained attempts, often related to ovulation or sperm production problems. The transcript repeatedly frames hCG as a fertility tool, including for men recovering after steroids.
Amenorrhea
Amenorrhea is the absence of menstrual periods, often reflecting hormonal or ovulatory dysfunction. The transcript notes older and ongoing gynecologic uses of hCG in women with reproductive hormone disorders.
Anovulatory infertility
Anovulatory infertility is infertility caused by failure to ovulate, preventing normal egg release for conception. The transcript states that hCG is used to address ovulation problems in women with this diagnosis.
Uterine bleeding
Uterine bleeding refers to abnormal bleeding from the uterus that may reflect hormonal or structural causes. The transcript mentions uterine bleeding as a historical female indication discussed in earlier medical literature.
Obesity
Obesity is a chronic condition of excess body fat that increases metabolic and cardiovascular risk. The transcript references obesity in historical prescribing, including the later criticized hCG diet era.
Depression
Depression is a mood disorder marked by persistent low mood, reduced interest, and functional impairment. The transcript lists depression among older proposed indications and later mentions mood concerns during recovery planning.
Angina
Angina is chest discomfort caused by reduced blood flow to heart muscle, usually from coronary disease. The transcript cites angina as an older, now outdated, reason hCG was once prescribed in men.
Prostatitis
Prostatitis is inflammation of the prostate that can cause pelvic pain and urinary symptoms in affected men. The transcript includes prostatitis as another historical male indication noted in older sources.

Key Takeaways

  • hCG is presented as an older hormone therapy now used mainly for fertility and recovery contexts.
  • The transcript explains that hCG stimulates testicular cells directly, bypassing suppressed pituitary signaling during steroid use.
  • Using hCG with testosterone may help some men reduce testicular atrophy, but injection burden and cost are real limitations.
  • Potential downsides discussed include estradiol rise, systemic edema, and possible long‑term cellular desensitization concerns.
  • For fertility attempts, the transcript emphasizes stopping testosterone and using structured hCG dosing for several months.